Evidence map›Paper›PMID 42135764›Full record

ArticleJournal of experimental & clinical cancer research : CR2026

Bi-directional regulation between NAD/NAMPT and IFN-γ/PD-L1 axes via BRD4/IRF1 and mitochondrial respiration in metastatic cutaneous melanoma.

Irene Fiorilla, Beatrice Ghezzi, Alessia Ponzano, Enrico Moiso, Federica Riccardo, Nicoletta Tommasi, Lidia Avalle, Giovanna Carrà, Filippo Ugolini, Edoardo Calussi and 13 more

Abstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Irene FiorillaDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Beatrice GhezziDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Alessia PonzanoDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Enrico MoisoDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Federica RiccardoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Turin, Torino, Italy.
Nicoletta TommasiDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Lidia AvalleDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Giovanna CarràSan Luigi Gonzaga Hospital, Regione Gonzole, Orbassano, Italy.
Filippo UgoliniHistopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.
Edoardo CalussiHistopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.
Alberto Maria TodescoDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Sabrina DigiovanniDepartment of Oncology, Molecular Biotechnology Center "Guido Tarone", University of Turin, Torino, Italy.
Filippo CasoneDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Giulia RizzaDepartment of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy.
Luca PonzoneDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Turin, Torino, Italy.
Anna Szumera-CiećkiewiczBiobank, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Maria CavalettoDepartment of Sustainable Development and Ecological Transition, University of Eastern Piedmont, Vercelli, Italy.
Paolo Ettore PorporatoDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Turin, Torino, Italy.
Laura ContiDepartment of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Turin, Torino, Italy.
Chiara RigantiDepartment of Oncology, Molecular Biotechnology Center "Guido Tarone", University of Turin, Torino, Italy.
Daniela MassiDepartment of Health Sciences, Section of Pathology, University of Florence, Florence, Italy.
Enzo Calautti *Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center "Guido Tarone", University of Turin, Torino, Italy.
Valentina Audrito *Department of Science and Technological Innovation, University of Eastern Piedmont, Alessandria, Italy. valentina.audrito@uniupo.it.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Fondazione AIRC per la ricerca sul cancro ETS IG2021 #25766Fondazione AIRC per la ricerca sul cancro ETS IG2023 #29259Fondazione AIRC per la ricerca sul cancro ETS IG2025 #30515Fondazione AIRC per la ricerca sul cancro ETS MFAG2021 #26004Fondazione AIRC per la ricerca sul cancro ETS Programma di Ricerca 5 per Mille 2018 grant Id:21073Fondo di Beneficenza Intesa SanPaolo grant Id:B/2024/0194 NAMPTMinistero della Salute Ricerca Finalizzata Giovani Ricercatori-GR-2021-12374957NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

backgroundMetastatic cutaneous melanoma (MCM) is primarily treated with BRAF/MEK inhibitors and immune checkpoint inhibitors (ICIs), but the long-term efficacy of these therapies is often limited by acquired resistance. Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in NAD biosynthesis, is frequently upregulated in MCM, supporting metabolic rewiring and targeted therapy resistance. Interferon-γ (IFN-γ) signaling plays a central role in melanoma biology, exerting both antitumor and immunoregulatory effects, linked with the onset of therapeutic resistance. Emerging evidence suggests that metabolic pathways may critically modulate IFN-γ responses; however, the functional interplay between NAD/NAMPT metabolism and IFN-γ signaling in melanoma cells remains poorly defined.

methodsWe integrated transcriptomic, bioinformatic, biochemical, and functional approaches in human and murine melanoma cell lines, together with analyses of TCGA datasets and a tissue microarray (TMA) cohort. Mechanistic studies included pharmacological and genetic perturbation of Bromodomain and Extra-Terminal motif (BET) epigenetic factor BRD4, Interferon Regulatory Factor 1 (IRF1), and NAMPT, chromatin immunoprecipitation (ChIP) assays, and metabolic analyses. Tumor-T cell co-culture systems were used to assess the impact of melanoma-cell NAMPT modulation on T-cell behavior.

resultsIFN-γ induced NAMPT expression through a BRD4/IRF1-dependent transcriptional program. In turn, NAMPT activity was required to sustain IFN-γ signaling, as its inhibition impaired STAT1 activation and downstream transcriptional responses. Mechanistically, NAMPT-dependent NAD metabolism supported mitochondrial complex I activity and oxidative metabolism and was required for efficient BRD4 recruitment to IFN-responsive promoters, including CD274/PD-L1 and NAMPT itself. Across melanoma datasets and patient samples, NAMPT expression correlated with IFN-γ-responsive genes, including PD-L1. Functionally, modulation of NAMPT in melanoma cells influenced T-cell cytotoxicity and migration in co-culture systems.

conclusionsOverall, these findings identify NAMPT as a key metabolic component of the IFN-γ response network in melanoma cells, establishing a feed-forward regulatory circuit linking cytokine signaling, chromatin regulation, and mitochondrial metabolism. This work provides a framework to investigate how metabolic control of IFN-γ signaling shapes tumor-immune interactions.

Indexed as

B7-H1 AntigenCell Cycle ProteinsCytokinesInterferon-gammaInterferon Regulatory Factor-1MelanomaMitochondriaNADNicotinamide PhosphoribosyltransferaseSkin NeoplasmsTranscription FactorsAnimalsBromodomain Containing ProteinsCell Line, TumorCutaneous Malignant MelanomaGene Expression Regulation, NeoplasticB7-H1 AntigenBRD4 protein, humanBromodomain Containing ProteinsCD274 protein, humanCell Cycle ProteinsCytokinesInterferon-gammaInterferon Regulatory Factor-1IRF1 protein, humanNADNicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanTranscription FactorsBET proteinInflammationInterferonMetastatic melanomaMitochondrial respirationNADNAMPTPD-L1Tumor microenvironment

Identifiers

PMID42135764
PMCPMC13326467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.